- What kind of PhIIb data is worth $4B cash? Takeda’s Andy Plump has some thoughts on that Endpoints News
- ‘We’ll look back and say that this was a bargain.’ Takeda reveals first data from its $4 billion autoimmune disease pill. The Boston Globe
- Takeda Announces Positive Results in Phase 2b Study of Investigational TAK-279, an Oral, Once-Daily TYK2 Inhibitor, in People with Moderate-to-Severe Plaque Psoriasis businesswire.com
- Takeda’s $4 Billion Psoriasis Pill Helped Clear Skin in Mid-Stage Study Bloomberg
- Takeda raised to Buy at BofA on growth prospects and debt repayment (NYSE:TAK) Seeking Alpha
- View Full Coverage on Google News
Read original article here